Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

NCT02052310 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1043

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia in Incident Dialysis Patients

Interventions

DRUG: Roxadustat
DRUG: Epoetin Alfa

Sponsor

Kyntra Bio

Collaborators

[object Object]
[object Object]